Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 2
How Aggressive to Treat Hypertension
Some Early Views on the Controversy
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 3
Stroke and IHD Mortality vs Systolic BP by Age
Age at risk Age at risk:
256 80-89 years 80-89 years
(Floating absolute risk and 95% CI)
256
128 70-79 years 70-79 years
128
64 60-69 years 64 60-69 years
32 32
50-59 years 50-59 years
Mortality
16 16
40-49 years
8 8
4 4
2 2
1 1
Stroke Ischemic Heart Disease
0 0
120 140 160 180 120 140 160 180
Usual Systolic BP (mm Hg) Usual Systolic BP (mm Hg)
Lancet. 2002;360:1903-1913
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 4
BP Reductions as Small as 2 mmHg Reduce
the Risk of CV Events by Up to 10%
0
Risk reduction (%)
-10
-20
-30
-40
-50 ↓ 20%
-60
-70 ↓ 40%
-80 ↓ 50%
-90
-100
Heart failure Stroke Cardiovascular
death
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 6
Lifestyle Modifications
* Released in 2003
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 7
JNC-8 Significantly NHLBI Drops Out of
Delayed Guidelines Business
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 8
James et al JAMA December 13 2014
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 9
James et al JAMA December 13 2014
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 10
JNC-8 Hypertension Treatment Choices
Hypertension. 2010;56(2):196-202
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 16
VALISH Trial
Hypertension. 2010;56(2):196-202
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 17
RCTs Evaluating SBP Targets
in those Aged < 60
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 18
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 19
Guidelines, Performance Measures and Policy
• Guideline:
– In past: practical advice on a course of action
– Have become: RCT-based, rigorous
• Performance Measures:
– Distillation of guidelines:
• Use strict criteria to define what should and must
be done to avoid a quality concern
– Often applied to public reporting or financial
incentives
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 20
BP Treatment Targets Have Risks Both Ways
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 21
JNC-8 Implications for US
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 22
Major Findings
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 23
Conclusions
• In interim: My view:
– Aim for 140/90 but allow for individualization
– What’s your take?
All Rights Reserved, Duke Medicine 2007 sb/Strategy & Innovation Group | 24